The drug, called xylazine, is primarily found in heroin and illicit fentanyl, the FDA said, and overdoses can look similar to an opioid overdose.
A powerful animal tranquilizer is increasingly showing up in the illicit drug supply, putting unsuspecting users at risk for hard to treat overdoses and dangerous side effects, the Food and Drug Administration warned Tuesday., the FDA said, and overdoses can look similar to an opioid overdose.can't be reversed using the antidote naloxone, or Narcan.
In humans, it can lead to profound sedation that can last for hours. It's also linked with gaping skin wounds not seen with other injectable drug use, the FDA said. Though mainly mixed with opioids, the agency said, xylazine has also been detected in stimulants such as cocaine andMedications used to help patients with opioid use disorder won't work in someone who has become dependent on xylazine.
Because the drug isn't included in routine toxicology screenings, the FDA added, it may be underdetected inXylazine is sold on the street under several names, including tranq, tranq dope, sleep-cut, Philly dope and zombie drug, it said.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA warns of risks from xylazine, an animal drug linked to overdoses in humansThe Food and Drug Administration warned that overdoses from xylazine mirror opioid overdoses, but may not be reversed by naloxone.
Baca lebih lajut »
FDA links opioid overdoses to animal sedative not for human consumptionThe FDA says overdoses caused by the animal medication xylazine is hard to distinguish from opioids for humans.
Baca lebih lajut »
An animal tranquilizer is increasingly showing up in street drugsThe FDA says a powerful animal tranquilizer is increasingly showing up in the illicit drug supply, putting unsuspecting users at risk for hard to treat overdoses and dangerous side effects.
Baca lebih lajut »
Why There Isn’t an RSV Vaccine to Combat the Current SurgePfizer will submit results of a phase 3 trial to the FDA soon.
Baca lebih lajut »
U.S.FDA panel votes against Veru's COVID-19 pillA panel of outside advisers to the U.S. health regulator on Wednesday voted against authorizing Veru Inc's drug for treating high-risk patients hospitalized with COVID-19, citing multiple concerns over efficacy and safety data being based on a small trial.
Baca lebih lajut »